ABL1 (Q252H)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.Q252H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Bosutinib | 98.7% | 1.3% | 87.22 |
| 2 | Dasatinib | 98.3% | 1.7% | 87.97 |
| 3 | Ponatinib | 97.0% | 3.0% | 78.23 |
| 4 | Nilotinib | 94.0% | 6.0% | 96.49 |
| 5 | Nintedanib | 93.8% | 6.2% | 90.23 |
| 6 | Axitinib | 89.0% | 11.0% | 93.23 |
| 7 | Brigatinib | 81.8% | 18.2% | 82.96 |
| 8 | Vandetanib | 81.4% | 18.6% | 95.74 |
| 9 | Crizotinib | 76.4% | 23.6% | 91.39 |
| 10 | Pacritinib | 75.5% | 24.5% | 88.64 |
| 11 | Repotrectinib | 70.5% | 29.5% | 84.21 |
| 12 | Tivozanib | 69.8% | 30.2% | 92.42 |
| 13 | Canertinib | 67.9% | 32.1% | 96.49 |
| 14 | Erdafitinib | 62.9% | 37.1% | 95.71 |
| 15 | Entrectinib | 48.4% | 51.6% | 93.69 |
| 16 | Dacomitinib | 41.1% | 58.9% | 97.99 |
| 17 | Ripretinib | 39.3% | 60.7% | 92.95 |
| 18 | Fedratinib | 39.0% | 61.0% | 96.21 |
| 19 | Erlotinib | 35.8% | 64.2% | 99.75 |
| 20 | Imatinib | 30.6% | 69.4% | 99.00 |
| 21 | Sunitinib | 27.9% | 72.1% | 91.73 |
| 22 | Afatinib | 24.9% | 75.1% | 98.50 |
| 23 | Lenvatinib | 24.1% | 75.9% | 97.74 |
| 24 | Selpercatinib | 21.7% | 78.3% | 96.72 |
| 25 | Avapritinib | 20.0% | 80.0% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Bosutinib | 98.7% | 99.7% | -1.0% |
| Dasatinib | 98.3% | 98.6% | -0.3% |
| Ponatinib | 97.0% | 100.0% | -3.0% |
| Nilotinib | 94.0% | 98.0% | -4.0% |
| Nintedanib | 93.8% | 99.9% | -6.1% |
| Axitinib | 89.0% | 99.4% | -10.4% |
| Brigatinib | 81.8% | 82.8% | -1.1% |
| Vandetanib | 81.4% | 95.7% | -14.3% |
| Crizotinib | 76.4% | 97.0% | -20.6% |
| Pacritinib | 75.5% | 92.0% | -16.5% |
| Repotrectinib | 70.5% | 93.6% | -23.1% |
| Tivozanib | 69.8% | 95.8% | -26.1% |
| Canertinib | 67.9% | 91.6% | -23.6% |
| Erdafitinib | 62.9% | 90.9% | -28.0% |
| Entrectinib | 48.4% | — | — |
| Dacomitinib | 41.1% | 80.8% | -39.8% |
| Ripretinib | 39.3% | 82.9% | -43.6% |
| Fedratinib | 39.0% | 82.7% | -43.7% |
| Erlotinib | 35.8% | — | — |
| Imatinib | 30.6% | 86.2% | -55.5% |
| Sunitinib | 27.9% | — | — |
| Afatinib | 24.9% | — | — |
| Lenvatinib | 24.1% | 76.3% | -52.2% |
| Selpercatinib | 21.7% | — | — |
| Avapritinib | 20.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms